FDA enforcement of homeopathic products has shifted substantially in recent years. The 1988 FDA Compliance Policy Guide 400.400, which had governed homeopathic products for decades, was withdrawn in 2019. Subsequent guidance established a risk-based enforcement approach with increasing attention to specific claim categories. This post covers what naturopathic, integrative, and wellness practices marketing or dispensing homeopathic products should understand.
Regulatory history and current framework
The 1988 FDA Compliance Policy Guide 400.400 provided a relatively permissive framework for homeopathic products meeting specific criteria. Under it, homeopathic drugs listed in the HPUS (Homoeopathic Pharmacopoeia of the United States) operated with less FDA premarket scrutiny than other drug categories.
FDA withdrew CPG 400.400 in 2019, signaling a shift toward standard drug-regulation treatment of homeopathic products. Subsequent FDA guidance established a risk-based enforcement approach focusing on products with specific safety or efficacy concerns.
What FDA specifically targets
Disease-treatment claims on homeopathic products
Homeopathic products marketed with specific disease treatment claims (cancer, Alzheimer’s, autism, serious chronic conditions) have drawn specific enforcement.
Pediatric safety issues
Homeopathic products marketed for pediatric use with safety issues (contamination, improper labeling, specific dangerous ingredients) have produced enforcement actions.
Unapproved new drug status
Homeopathic products marketed with specific therapeutic claims meet the FDA’s definition of drugs under 201(g) and are technically unapproved new drugs without FDA approval.
Quality manufacturing issues
Homeopathic products with cGMP (current Good Manufacturing Practices) deficiencies have drawn enforcement regardless of the underlying marketing claims.
Marketing considerations for practices
Dispensing homeopathic products
Naturopathic and integrative practices often dispense homeopathic products as part of clinical care. Marketing considerations:
- Specific disease-treatment claims on dispensed products create compliance exposure.
- Marketing products for serious conditions (cancer, autoimmune, neurodegenerative) is particularly high-risk.
- Pediatric homeopathic product marketing faces heightened scrutiny.
- Private-label homeopathic lines carry additional manufacturing-compliance considerations.
Practice marketing referring to homeopathy
Practice marketing about homeopathy generally (as a modality) is different from marketing specific homeopathic products. Educational content about homeopathy is generally lower-risk than product-specific outcome claims.
Practitioner credentialing
Homeopathic practitioner credentials (CCH, DHt, others) have specific meanings. Marketing credentials should reflect actual certification.
The FTC layer
Beyond FDA, the FTC has pursued homeopathic product marketing under substantiation rules. The FTC has been particularly active on homeopathic products marketed with specific efficacy claims that don’t meet the competent-and-reliable-scientific-evidence standard.
FTC guidance on homeopathic advertising requires either competent-and-reliable scientific evidence for efficacy claims or clear disclosure that claims are based on traditional homeopathic theories without accepted scientific support.
Compliant homeopathic marketing framework
- Avoid specific disease-treatment claims.Homeopathic marketing with specific disease outcome claims is the highest-risk pattern.
- Use appropriate FTC-required framing.If making efficacy claims based on traditional homeopathic theory, include the required disclosure.
- Verify manufacturing compliance for products you dispense.Your supplier’s cGMP posture affects your risk.
- Conservative pediatric-product marketing.Pediatric homeopathic products warrant particular care.
- Educational rather than promotional framing.Homeopathy as a modality can be discussed educationally; product-specific promotional marketing is higher-risk.
Frequently asked questions
Can I still market homeopathic remedies?
Yes, with appropriate framing. Specific disease-treatment claims create significant exposure; general modality education is generally lower-risk.
What about homeopathic products for specific conditions?
Specific condition claims trigger FDA drug-claim rules and FTC substantiation rules. Marketing products for specific conditions without substantiation is high-risk.
Does FTC require a specific disclaimer on homeopathic ads?
FTC guidance establishes requirements around homeopathic efficacy claims. Specific disclosure language may be required when claims are based on traditional theory rather than modern scientific evidence.
What about HPUS-listed products?
HPUS listing doesn’t exempt products from FDA drug rules under the current framework. Marketing HPUS-listed products still follows general claim rules.
Are there safer sub-categories?
Products marketed for general wellness without specific disease claims face lower exposure than disease-targeted products. Products for minor self-limiting conditions face lower exposure than serious-condition products.
Should naturopathic practices dispense homeopathic products?
This is a clinical and business decision beyond pure compliance. The compliance question is how the products are marketed and dispensed, not whether they’re dispensed.